AQR Capital Management LLC Has $604,000 Position in Moderna, Inc. (NASDAQ:MRNA)

AQR Capital Management LLC grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 32.0% during the second quarter, HoldingsChannel reports. The firm owned 5,083 shares of the company’s stock after buying an additional 1,232 shares during the quarter. AQR Capital Management LLC’s holdings in Moderna were worth $604,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Profund Advisors LLC boosted its stake in shares of Moderna by 20.9% in the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after purchasing an additional 9,719 shares in the last quarter. Marshall Wace LLP boosted its position in Moderna by 295.5% during the 2nd quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock worth $4,180,000 after buying an additional 26,300 shares during the period. Illinois Municipal Retirement Fund boosted its position in Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after buying an additional 9,360 shares during the period. Swedbank AB acquired a new stake in Moderna during the 1st quarter worth approximately $3,315,000. Finally, Wellington Management Group LLP boosted its position in Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after buying an additional 1,614,460 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of MRNA stock opened at $57.73 on Tuesday. The firm has a market capitalization of $22.12 billion, a PE ratio of -3.68 and a beta of 1.66. The firm has a fifty day simple moving average of $72.93 and a two-hundred day simple moving average of $105.95. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12 month low of $55.70 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.62) EPS. Analysts forecast that Moderna, Inc. will post -9.85 EPS for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the topic of several recent research reports. Piper Sandler cut their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. TD Cowen cut their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Bank of America dropped their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $100.44.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,184 shares of company stock worth $5,647,531 in the last quarter. 15.70% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.